SG11202007873VA - Treatment of tumors by a combination of an oncolytic adenovirus and a cdk4/6 inhibitor - Google Patents
Treatment of tumors by a combination of an oncolytic adenovirus and a cdk4/6 inhibitorInfo
- Publication number
- SG11202007873VA SG11202007873VA SG11202007873VA SG11202007873VA SG11202007873VA SG 11202007873V A SG11202007873V A SG 11202007873VA SG 11202007873V A SG11202007873V A SG 11202007873VA SG 11202007873V A SG11202007873V A SG 11202007873VA SG 11202007873V A SG11202007873V A SG 11202007873VA
- Authority
- SG
- Singapore
- Prior art keywords
- cdk4
- tumors
- inhibitor
- treatment
- combination
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/761—Adenovirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18000210 | 2018-03-05 | ||
| PCT/EP2019/000067 WO2019170283A1 (en) | 2018-03-05 | 2019-03-05 | Treatment of tumors by a combination of an oncolytic adenovirus and a cdk4/6 inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202007873VA true SG11202007873VA (en) | 2020-09-29 |
Family
ID=61569019
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202007873VA SG11202007873VA (en) | 2018-03-05 | 2019-03-05 | Treatment of tumors by a combination of an oncolytic adenovirus and a cdk4/6 inhibitor |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20210038661A1 (en) |
| EP (1) | EP3762004B1 (en) |
| JP (1) | JP2021517119A (en) |
| KR (1) | KR20210031852A (en) |
| CN (1) | CN112533620A (en) |
| AU (1) | AU2019232768A1 (en) |
| CA (1) | CA3092907A1 (en) |
| DK (1) | DK3762004T3 (en) |
| ES (1) | ES2965632T3 (en) |
| FI (1) | FI3762004T3 (en) |
| HU (1) | HUE064471T2 (en) |
| SG (1) | SG11202007873VA (en) |
| WO (1) | WO2019170283A1 (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2020342594A1 (en) * | 2019-09-05 | 2022-03-10 | Klinikum Rechts Der Isar Der Technischen Universität München | Treatment of tumors by a combination of an oncolytic adenovirus, a CDK4/6 inhibitor and a further therapeutically active agent |
| KR102341347B1 (en) * | 2019-11-28 | 2021-12-20 | 의료법인 성광의료재단 | Compositions, kits and methods for diagnosing cancer resistant to cancer therapeutics |
| WO2024043322A1 (en) * | 2022-08-25 | 2024-02-29 | 富士フイルム株式会社 | Method for producing targe viruses and culture composition |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK0533838T3 (en) | 1990-06-11 | 1998-02-23 | Nexstar Pharmaceuticals Inc | Nucleic acid |
| WO1998008856A2 (en) | 1996-08-30 | 1998-03-05 | Fuerste Jens Peter | Mirror-symmetrical selection and evolution of nucleic acids |
| DE19742706B4 (en) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | lipocalin muteins |
| WO2003099859A2 (en) | 2002-05-27 | 2003-12-04 | Per Sonne Holm | Novel use of adenoviruses and nucleic acids coding therefor |
| WO2004035616A2 (en) * | 2002-10-15 | 2004-04-29 | Per Sonne Holm | Adenovirus expressing genes in reverse order and use thereof |
| AU2003271730A1 (en) * | 2002-10-15 | 2004-05-04 | Per Sonne Holm | Novel adenoviruses, nucleic acids coding therefor, and use thereof |
| CA2590257A1 (en) * | 2003-11-14 | 2005-06-09 | Per Sonne Holm | Novel adenoviruses, nucleic acids that code for the same and the use of said viruses |
| AU2012279117A1 (en) * | 2011-07-01 | 2014-01-09 | Novartis Ag | Combination therapy comprising a CDK4/6 inhibitor and a PI3K inhibitor for use in the treatment of cancer |
| EP2971008B1 (en) * | 2013-03-14 | 2018-07-25 | Salk Institute for Biological Studies | Oncolytic adenovirus compositions |
| JP2016520118A (en) * | 2013-05-28 | 2016-07-11 | ノバルティス アーゲー | Pyrazolo-pyrrolidin-4-one derivatives as BET inhibitors and their use in the treatment of diseases |
| KR20160037201A (en) * | 2013-08-06 | 2016-04-05 | 온코에틱스 게엠베하 | Method of treating diffuse large b-cell lymphoma (dlbcl) using a bet-bromodomain inhibitor |
| KR101787680B1 (en) * | 2013-12-31 | 2017-10-19 | 수안주 파마 코포레이션 리미티드 | Kinase Inhibitor and Use Thereof |
| US9682933B2 (en) * | 2014-05-30 | 2017-06-20 | British Columbia Cancer Agency Branch | Androgen receptor modulators and methods for their use |
| US11000560B2 (en) * | 2015-05-04 | 2021-05-11 | Vcn Biosciences, S.L. | Oncolytic adenoviruses with mutations in immunodominant adenovirus epitopes and their use in cancer treatment |
-
2019
- 2019-03-05 AU AU2019232768A patent/AU2019232768A1/en active Pending
- 2019-03-05 DK DK19710999.4T patent/DK3762004T3/en active
- 2019-03-05 CA CA3092907A patent/CA3092907A1/en active Pending
- 2019-03-05 CN CN201980016785.2A patent/CN112533620A/en active Pending
- 2019-03-05 KR KR1020207025771A patent/KR20210031852A/en active Search and Examination
- 2019-03-05 HU HUE19710999A patent/HUE064471T2/en unknown
- 2019-03-05 FI FIEP19710999.4T patent/FI3762004T3/en active
- 2019-03-05 EP EP19710999.4A patent/EP3762004B1/en active Active
- 2019-03-05 WO PCT/EP2019/000067 patent/WO2019170283A1/en unknown
- 2019-03-05 US US16/978,048 patent/US20210038661A1/en active Pending
- 2019-03-05 SG SG11202007873VA patent/SG11202007873VA/en unknown
- 2019-03-05 ES ES19710999T patent/ES2965632T3/en active Active
- 2019-03-05 JP JP2020546331A patent/JP2021517119A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2019232768A1 (en) | 2020-09-03 |
| RU2020132466A3 (en) | 2022-04-05 |
| WO2019170283A1 (en) | 2019-09-12 |
| EP3762004B1 (en) | 2023-09-13 |
| KR20210031852A (en) | 2021-03-23 |
| WO2019170283A8 (en) | 2019-11-07 |
| FI3762004T3 (en) | 2023-12-11 |
| US20210038661A1 (en) | 2021-02-11 |
| ES2965632T3 (en) | 2024-04-16 |
| RU2020132466A (en) | 2022-04-05 |
| HUE064471T2 (en) | 2024-03-28 |
| CN112533620A (en) | 2021-03-19 |
| EP3762004A1 (en) | 2021-01-13 |
| CA3092907A1 (en) | 2019-09-12 |
| DK3762004T3 (en) | 2023-11-27 |
| JP2021517119A (en) | 2021-07-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL272948B1 (en) | Enpp1 inhibitors and their use for the treatment of cancer | |
| EP3600281A4 (en) | Combination therapy for the treatment or prevention of tumours | |
| IL261721A (en) | Combinations of lsd1 inhibitors for use in the treatment of solid tumors | |
| IL276103A (en) | Cd70 combination therapy | |
| IL279260A (en) | Kdm1a inhibitors for the treatment of disease | |
| SG11202007873VA (en) | Treatment of tumors by a combination of an oncolytic adenovirus and a cdk4/6 inhibitor | |
| GB201820450D0 (en) | Compound and its use for the treatment of alpha1-antitryspin deficiency | |
| HK1253279A1 (en) | Combinations of a phosphoinositide 3-kinase inhibitor compound and a cdk4/6 inhibitor compound for the treatment of cancer | |
| IL290011A (en) | Ezh2 inhibition in combination therapies for the treatment of cancers | |
| MX2018010709A (en) | Cancer therapy with an oncolytic virus combined with a checkpoint inhibitor. | |
| IL284225A (en) | Combination treatment for solid tumors using docetaxel and a cyp3a inhibitor | |
| IL290373A (en) | Combinations of tgfb inhibitors and cdk inhibitors for the treatment of breast cancer | |
| IL281244A (en) | Combination therapy for the treatment of liver disease | |
| BR112019003722A2 (en) | combination therapies for the treatment of hepatocellular carcinoma | |
| SG11202111820PA (en) | Oncolytic adenovirus and checkpoint inhibitor combination therapy | |
| EP3801473A4 (en) | Setbp1 inhibitors for the treatment of myeloid neoplasms and solid tumors | |
| EP3790895A4 (en) | Ccl21 and checkpoint inhibitors for the treatment of cancer | |
| EP3774799C0 (en) | Nek6 kinase inhibitors useful for the treatment of solid tumors | |
| IL285221A (en) | Use of oncolytic viruses for the treatment of cancer | |
| IL287050A (en) | Compounds for the treatment of oncovirus induced cancer and methods of use thereof | |
| EP3697413A4 (en) | Combination therapy of fractionated radiation and sapc-dops for the treatment of tumors | |
| EP3603635A4 (en) | Use of melatonin for the treatment of tumours | |
| IL279000A (en) | Agi-134 combined with a checkpoint inhibitor for the treatment of solid tumors | |
| HUP1900281A1 (en) | Use of monoamine-oxidase-b inhibitors in the prevention or treatment of prostate cancer | |
| GB201917701D0 (en) | CD70 Combination therapy |